The Skolkovo Foundation (part of the VEB.RF Group) and AO Pharmasintez have signed a partnership agreement to establish an R&D center of the pharmaceutical group in the Skolkovo Innovation Center.
“The center will combine auxiliary laboratory infrastructure for conducting applied research, developing new drug formulations, and preparing materials for clinical and preclinical trials,” the Foundation’s press service reported.
Construction of the complex with an area of 15,000 square meters will begin at the end of this year, with completion planned for 2030. The amount of investment in the project was not disclosed in the statement.
According to Vikram Punia, founder and president of the Pharmasintez Group, the center will focus on “the development and implementation of innovative drugs.” To achieve this, plans are in place to attract both Russian scientists and “international intellectual and technological expertise.”
In turn, Sergei Perov, Chairman of the Foundation’s Board, described the appearance of the Pharmasintez research center in Skolkovo as “a step towards creating a full cycle of pharmaceutical innovation—from idea to finished drug.”